The first breakthrough in personalizing CF treatments came with the approval of ivacaftor (KalydecoTM from Vertex Pharmaceuticals) for patients bearing G551D-CFTR in at least one allele, initially licensed by the FDA and later by the European Medicines Agency (EMA). The gene discussed is CFTR; the disease is cystic fibrosis.